Back to Insights

As clinical trials become more complex and competitive, the role of medical imaging has never been more critical. From initial protocol design to final regulatory submission, high-quality, efficient imaging operations can make or break a study’s success.

Yet many Contract Research Organizations (CROs) are still relying on imaging partnerships and technologies that simply can’t keep pace. If you’re experiencing any of these five red flags, it may be time to re-evaluate your imaging strategy.

1. Manual Quality Control Processes

Manual quality control (QC) is slow, inconsistent, and expensive. When QC depends on human review for every study, issues such as motion artifacts, incorrect contrast timing, or incomplete anatomical coverage are often caught days or weeks later, necessitating re-scans, protocol amendments, or compromised endpoints.

Modern imaging operations use automated, AI-enabled QC that inspects images in real time, flags likely problems, and provides actionable guidance to the site.

Practical Example An automated QC system can detect suboptimal contrast enhancement immediately after acquisition and prompt a technologist to repeat a scan while the patient is still onsite, avoiding schedule disruption and data loss.

2. Lack of Centralized Data Monitoring

Trials that aggregate imaging from dozens of sites across regions require a single source of truth. When data handling relies on email attachments, FTP transfers, or sporadic uploads, sponsors lose visibility into image flow, QC status, and reader workloads.

Centralized, cloud-based platforms ingest imaging directly from sites, apply standardized QC checks, and present unified dashboards for remote monitoring.

Practical Example A centralized dashboard highlights sites with recurring protocol deviations (e.g., slice thickness or field-of-view errors), allowing targeted retraining and preventing broader data quality erosion.

3. Insufficient Therapeutic Expertise

Imaging needs differ by therapeutic area and modality. A generalist imaging vendor may miss subtle protocol optimizations that preserve critical endpoints, such as contrast timing in hepatic MRI for oncology studies or specific diffusion protocols for neurology trials.

Best-in-class imaging CROs create therapeutic Centers of Excellence that embed modality- and disease-specific expertise into protocol design, reader selection, and QC criteria.

Practical Example Early involvement of an imaging therapeutic specialist can adjust acquisition windows to capture transient contrast kinetics, preserving a quantitative biomarker that would otherwise be unusable.

4. Inability to Support Decentralized Trials

Decentralized and hybrid models introduce new imaging workflows: mobile units, satellite clinics, and even supervised home-based imaging. These settings demand logistics coordination, remote training, and QC that tolerates greater variability.

CROs that cannot support remote onboarding, mobile scheduling, or automated QC for unsupervised acquisitions will struggle to deliver consistent, regulatory-grade data.

Practical Example A sponsor using mobile MRI vans benefits from a CRO that manages scheduling, ensures scanner calibration across vehicles, and provides real-time QC so mobile teams can correct issues immediately.

5. Reactive, Not Proactive Approach

Imaging partners should be strategic advisors, not order-takers. A reactive CRO waits for RFPs and implements standard workflows; a proactive partner advises on imaging endpoints, anticipates regulatory expectations, integrates new technologies, and proposes efficiencies that reduce cost and timeline risk.

Practical Example During protocol drafting, a proactive imaging CRO identifies simpler, more robust surrogate measures or more practical acquisition windows that lower site burden and improve recruitment feasibility.

Expanding the Conversation: Practical Examples and What to Expect

Protocol Design

Expect imaging input during protocol development, including proposed sequences, timing windows, and site qualification criteria. This reduces amendments and data loss later.

Site Qualification and Training

Robust CROs perform remote scanner checks, provide standardized training modules, and monitor site performance with follow-up coaching when deviations appear.

Vendor Neutrality and Interoperability

Imaging ecosystems should support common DICOM standards and integrate with sponsor data lakes and eCRFs to streamline downstream analyses.

Change Management

When new scanners, sites, or modalities are introduced mid-study, the CRO should have a documented process for validation, reader recalibration, and bridging analyses.

Checklist: Questions to Ask Prospective Imaging CROs

  1. How do you perform QC? Is it automated, manual, or hybrid? Can you demonstrate turnaround times and error-reduction workflows?
  2. Do you provide a centralized platform for image ingestion, monitoring, and reporting? Can sponsors view dashboards in real time?
  3. What therapeutic-area expertise do you offer? Do you have Centers of Excellence or dedicated subject-matter experts for my indication?
  4. How do you support decentralized or hybrid imaging workflows (mobile units, remote sites, home-based imaging)?
  5. How do you handle protocol deviations, site retraining, and corrective actions? What metrics do you track to demonstrate improvement?
  6. What are your processes for reader qualification, inter-reader variability management, and adjudication?
  7. How do you ensure interoperability with sponsor systems and compliance with regulatory requirements for imaging data?
  8. Can you provide sample SOPs, turnaround metrics, and a client reference with similar trial complexity (if available)?

Conclusion

In an era of escalating trial complexity and heightened sponsor expectations, the bar for imaging CRO capabilities has never been higher. Those who cling to outdated processes and technologies simply won’t be able to keep pace.

The most successful CROs are re-inventing their imaging operations from the ground up — leveraging AI, cloud computing, and deep therapeutic expertise to deliver unparalleled quality, efficiency, and innovation.

Sponsors recognize this new standard and are increasingly aligning with CROs who can demonstrate a clear vision for the future of clinical imaging. If your current partner falls short in any of these key areas, it may be time for a change.

The right imaging CRO can be a true strategic asset, elevating your trial’s chances of success. But finding that partner requires a discerning eye and an understanding of the industry’s evolving best practices.

Schedule a strategy conversation to explore how GenPhase can support your clinical imaging programs.